Another preclinical study demonstrated that SAR737, an oral CHK1 inhibitor, combined with low-dose gemcitabine, enhanced the effect of PD-L1 blockade in SCLC by modulating the immune microenvironment (90). Here, CHEK1 is linked to small cell lung carcinoma.